Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alnylam Pharmaceut (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,274,534
  • Shares Outstanding, K 98,330
  • Annual Sales, $ 47,160 K
  • Annual Income, $ -410,110 K
  • 36-Month Beta 2.98
  • Price/Sales 158.13
  • Price/Cash Flow N/A
  • Price/Book 10.74

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.63 +7.08%
on 01/19/18
136.71 -3.95%
on 01/03/18
+7.36 (+5.93%)
since 12/22/17
3-Month
112.95 +16.26%
on 10/23/17
147.63 -11.05%
on 11/02/17
+16.62 (+14.49%)
since 10/20/17
52-Week
35.98 +264.97%
on 01/31/17
147.63 -11.05%
on 11/02/17
+92.36 (+237.05%)
since 01/20/17

Most Recent Stories

More News
Alnylam Pharmace Rises 3.82% on Heavy Volume: Watch For Potential Pullback

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $126.07 to a high of $130.43. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high...

ALNY : 131.27 (+5.16%)
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

ALNY : 131.27 (+5.16%)
BIVV : 103.60 (+61.60%)
SNY : 43.14 (-3.27%)
BIIB : 345.38 (+0.87%)
SmarTrend Watching for Potential Rebound in Shares of Alnylam Pharmace After 2.48% Loss

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $125.57 to a high of $131.02. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of...

ALNY : 131.27 (+5.16%)
Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead?

Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.

ALNY : 131.27 (+5.16%)
EXEL : 29.45 (+5.18%)
PRTA : 41.20 (+4.25%)
RHHBY : 30.7400 (+0.16%)
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.

ALNY : 131.27 (+5.16%)
REGN : 373.43 (+0.51%)
PFE : 36.82 (-0.32%)
SNY : 43.14 (-3.27%)
Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

XOMA : 34.00 (+1.25%)
ALNY : 131.27 (+5.16%)
EXEL : 29.45 (+5.18%)
SNY : 43.14 (-3.27%)
Alnylam Expands Alnylam Act(TM) Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has expanded the Alnylam Act(TM) program to include no-charge, third-party genetic...

ALNY : 131.27 (+5.16%)
Alnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 36th Annual J.P. Morgan...

JPM : 113.68 (+0.59%)
ALNY : 131.27 (+5.16%)
Alnylam to Webcast Presentation at Goldman Sachs Healthcare CEOs Unscripted Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs Healthcare...

ALNY : 131.27 (+5.16%)
5 of the Best-Performing Biotech Stocks of 2017

With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).

SGMO : 19.45 (+9.58%)
XOMA : 34.00 (+1.25%)
BLUE : 199.00 (+13.10%)
ALNY : 131.27 (+5.16%)
DVAX : 17.00 (+8.63%)
GILD : 81.22 (+0.30%)
PFE : 36.82 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 127.19
1st Resistance Point 126.01
Last Price 131.27
1st Support Level 123.14
2nd Support Level 121.45

See More

52-Week High 147.63
Last Price 131.27
Fibonacci 61.8% 104.98
Fibonacci 50% 91.81
Fibonacci 38.2% 78.63
52-Week Low 35.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.